In vivo efficacy of acyl CoA: diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Journal of Pharmacology

• Publication date

  2010-07-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ejphar.2010.03.056PMID 20385122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diacylglycerol Acyltransferase 1 Inhibition Lowers Serum Triglycerides in the Zucker Fatty Rat and the Hyperlipidemic Hamster

  2009cited by this paper
• Comparison of different methods to investigate postprandial lipaemia.

  2009cited by this paper
• Chylomicrons in disease—Future challenges

  2008cited by this paper
• Intestinal lipoprotein overproduction in insulin-resistant states

  2008cited by this paper
• Postprandial triglyceride responses to aerobic exercise and extended-release niacin.

  2008cited by this paper
• Chylomicrons in disease: a renaissance in lipidology International Symposium of Chylomicrons in Disease (ISCD), Lake Louise, Alberta, Canada, March 6th-8th, 2008.

  2008cited by this paper
• Insulin resistance and atherosclerosis.

  2008cited by this paper
• Therapeutic Effects of Fibrates in Postprandial Lipemia

  2008cited by this paper
• Reproducibility of postprandial lipemia tests and validity of an abbreviated 4-hour test.

  2008cited by this paper
• Fasting versus nonfasting triglycerides: implications for laboratory measurements.

  2008influential reference
• Are we ready for a prospective study to investigate the role of chylomicrons in cardiovascular disease?

  2008cited by this paper
• Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity.

  2008cited by this paper
• Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.

  2008cited by this paper
• Chylomicrons in disease-future challenges Invited keynote address.

  2008cited by this paper
• Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test?

  2008cited by this paper
• Mechanism of intestinal lipoprotein overproduction in insulin resistant humans.

  2008cited by this paper
• Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.

  2007influential reference
• Chylomicron and apoB 48 metabolism in the JCR : LA corpulent rat , a model for the metabolic syndrome

  2007cited by this paper
• Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.

  2007influential reference
• Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome.

  2007influential reference
• Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome.

  2007cited by this paper
• Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis.

  2006cited by this paper
• Atorvastatin or fenofibrate on post‐prandial lipaemia in type 2 diabetic patients with hyperlipidaemia

  2006cited by this paper
• Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster.

  2005cited by this paper
• Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels.

  2004cited by this paper
• Post-prandial triglyceride profile in a population-based sample of Type 2 diabetic patients

  2003cited by this paper
• Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1.

  2002influential reference
• Atherogenic progression of carotid stenosis associates selectively with monocyte fraction in circulating leukocytes

  2002cited by this paper
• Fasting and Postprandial Overproduction of Intestinally Derived Lipoproteins in an Animal Model of Insulin Resistance

  2002influential reference
• The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.

  2002cited by this paper
• Subendothelial retention of atherogenic lipoproteins in early atherosclerosis

  2002cited by this paper
• Interleukin‐1 receptor antagonist is detectable in human carotid artery plaques and is related to triglyceride levels and Chlamydia pneumoniae IgA antibodies

  2002cited by this paper
• DGAT1 Is Not Essential for Intestinal Triacylglycerol Absorption or Chylomicron Synthesis*

  2002influential reference
• High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists.

  2001cited by this paper
• Cloning of DGAT2, a Second Mammalian Diacylglycerol Acyltransferase, and Related Family Members*

  2001cited by this paper
• Postprandial hyperlipidemia in Zucker diabetic fatty fa/fa rats, an animal model of type II diabetes, and its amelioration by acyl-CoA:cholesterol acyltransferase inhibition.

  2001cited by this paper
• Postprandial lipoproteins and atherosclerosis.

  2001cited by this paper
• Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat

  2000cited by this paper
• Arterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats.

  2000cited by this paper
• The endothelium and lipoproteins: insights from recent cell biology and animal studies.

  2000cited by this paper
• Characterization of atherosclerosis in LDL receptor knockout mice: macrophage accumulation correlates with rapid and sustained expression of aortic MCP-1/JE.

  2000cited by this paper
• Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men.

  1999cited by this paper
• HDL metabolism in hypertriglyceridemic states: an overview.

  1999cited by this paper
• Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis.

  1998cited by this paper
• Resistance of chylomicron and VLDL remnants to post-heparin lipolysis in ApoE-deficient mice: the role of apoE in lipoprotein lipase-mediated lipolysis in vivo and in vitro.

  1998cited by this paper
• Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia.

  1993cited by this paper
• Mechanism of action of fibrates.

  1993cited by this paper
• Postprandial plasma lipoprotein changes in human subjects of different ages.

  1988cited by this paper
• Retarded chylomicron apolipoprotein-B catabolism in Type 2 (non-insulin-dependent) diabetic subjects with lipaemia

  1984cited by this paper
• Atherogenesis: a postprandial phenomenon.

  1979cited by this paper
• Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man.

  1973cited by this paper

• Lipid Droplet-Associated Proteins: Roles in Cardiovascular Diseases.

  2026cites this paper
• Substrates (Acyl‐CoA and Diacylglycerol) Entry and Products (CoA and Triacylglycerol) Egress Pathways in DGAT1

  2025cites this paper
• Theoretical Framework and Emerging Challenges of Lipid Metabolism in Cancer.

  2024cites this paper
• The role of DGAT1 and DGAT2 in regulating tumor cell growth and their potential clinical implications

  2024cites this paper
• Metabolic reprogramming and lipid droplets are involved in Zika virus replication in neural cells

  2023cites this paper
• The pro-inflammatory effect of triglyceride on human CD4+ T cells and experimental autoimmune uveitis.

  2022cites this paper
• Progress of potential drugs targeted in lipid metabolism research

  2022cites this paper
• Oral Fat Tolerance Test in Male and Female C57Bl/6 Mice

  2021influential citation
• Targeting DGAT1 Ameliorates Glioblastoma by Increasing Fat Catabolism and Oxidative Stress.

  2020cites this paper
• Hepatic synthesis of triacylglycerols containing medium-chain fatty acids is dominated by diacylglycerol acyltransferase 1 and efficiently inhibited by etomoxir

  2020cites this paper
• Lipid droplet formation drives pathogenic ILC2 responses in airway inflammation

  2020cites this paper
• Evaluating the appropriate oral lipid tolerance test model for investigating plasma triglyceride elevation in mice

  2020cites this paper
• Lipid-Droplet Formation Drives Pathogenic Group 2 Innate Lymphoid Cells in Airway Inflammation.

  2020cites this paper
• DGAT1 Inhibitor Suppresses Prostate Tumor Growth and Migration by Regulating Intracellular Lipids and Non-Centrosomal MTOC Protein GM130

  2019cites this paper
• Magnolol-mediated regulation of plasma triglyceride through affecting lipoprotein lipase activity in apolipoprotein A5 knock-in mice

  2018cites this paper
• Discovery of dimethyl pent-4-ynoic acid derivatives, as potent and orally bioavailable DGAT1 inhibitors that suppress body weight in diet-induced mouse obesity model.

  2018cites this paper
• How lipid droplets "TAG" along: Glycerolipid synthetic enzymes and lipid storage.

  2017cites this paper
• Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into postprandial gut peptide secretion

  2017cites this paper
• Proteomics of lipid accumulation and DGAT inhibition in HepG2 liver carcinoma cells

  2017cites this paper
• Novel role of a triglyceride-synthesizing enzyme: DGAT1 at the crossroad between triglyceride and cholesterol metabolism

  2016cites this paper
• Identification of a botanical inhibitor of intestinal diacylglyceride acyltransferase 1 activity via in vitro screening and a parallel, randomized, blinded, placebo-controlled clinical trial

  2015cites this paper
• Some molecular targets for antihyperlipidemic drug research.

  2014cites this paper
• Discovery of 6-phenylpyrimido[4,5-b][1,4]oxazines as potent and selective acyl CoA:diacylglycerol acyltransferase 1 (DGAT1) inhibitors with in vivo efficacy in rodents.

  2014cites this paper
• Cardiomyocyte-specific Loss of Diacylglycerol Acyltransferase 1 (DGAT1) Reproduces the Abnormalities in Lipids Found in Severe Heart Failure*

  2014cites this paper
• Diacylglycerol acyltransferase-1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats[S]

  2013cites this paper
• Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans.

  2013cites this paper
• Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight and modulates gut peptide release—Potential insight into mechanism of action

  2013cites this paper
• Acyl-CoA:diacylglycerol acyltransferase: molecular biology, biochemistry and biotechnology.

  2012cites this paper
• Effect of Cholesterol and /or Methionine on the Testis of Rats

  2012influential citation
• Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1.

  2012cites this paper
• Intestinal DGAT 1 defi ciency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying Gene

  2012cites this paper
• Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying

  2012cites this paper
• Inhibition of microsomal triglyceride transfer protein improves insulin sensitivity and reduces atherogenic risk in Zucker fatty rats

  2011cites this paper
• Thermogenesis and related metabolic targets in anti-diabetic therapy.

  2011cites this paper
• DGAT1 inhibitors as anti-obesity and anti-diabetic agents.

  2010cites this paper